Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

231
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
231
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

207
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
207
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

212
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
212
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

248
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
248
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

429
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
429
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

219
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of a Bayesian Dosing Calculator for Vancomycin in Critically Ill Geriatric Patients.

Therapeutic drug monitoring·2026
Same author

Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia.

Healthcare (Basel, Switzerland)·2026
Same author

Montelukast attenuates diclofenac sodium-induced cardiotoxicity in male rats via targeting Wnt/β-catenin pathway.

Scientific reports·2026
Same author

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2026
Same author

Bridging the Knowledge Gap: A National Survey on MASLD Awareness and Management Barriers in the Saudi Population.

Healthcare (Basel, Switzerland)·2025
Same author

Assessment of Job Satisfaction and Intention to Quit Job Among Pharmacists in Saudi Arabia.

Pharmacy (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

3.3K

Optimizing Gentamicin Dosing in Pediatric Oncology Patients.

Abdulrahman Alwhaibi1, Mohammed M Almutairi2, Sary Alsanea2

  • 1From the Department of Clinical Pharmacy.

The Pediatric Infectious Disease Journal
|January 6, 2026
PubMed
Summary

Gentamicin dosing in pediatric oncology patients requires individualization due to variable pharmacokinetics and high rates of augmented renal clearance. Optimal dosing strategies are crucial for achieving therapeutic targets and minimizing toxicity in this population.

Keywords:
Monte Carlo simulationaugmented renal clearancegentamicinoncologypediatricspharmacokinetics

More Related Videos

Kidney Regeneration in Adult Zebrafish by Gentamicin Induced Injury
06:25

Kidney Regeneration in Adult Zebrafish by Gentamicin Induced Injury

Published on: August 3, 2015

11.3K
The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms
05:57

The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms

Published on: July 2, 2013

13.8K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
06:19

Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections

Published on: October 11, 2024

3.3K
Kidney Regeneration in Adult Zebrafish by Gentamicin Induced Injury
06:25

Kidney Regeneration in Adult Zebrafish by Gentamicin Induced Injury

Published on: August 3, 2015

11.3K
The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms
05:57

The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms

Published on: July 2, 2013

13.8K

Area of Science:

  • Pharmacology
  • Pediatric Oncology
  • Clinical Pharmacy

Background:

  • Gentamicin is a key antibiotic for Gram-negative infections in children.
  • Pharmacokinetics (PK) of gentamicin are highly variable in pediatric oncology patients due to malignancy and chemotherapy.
  • Developing a population PK model is essential for optimizing gentamicin dosing in this group.

Purpose of the Study:

  • To develop a population PK model for gentamicin in pediatric oncology patients.
  • To identify optimal gentamicin dosing strategies for improved efficacy and safety.
  • To investigate the influence of oncology status on gentamicin PK.

Main Methods:

  • Retrospective multicenter study of pediatric patients (1 month-14 years) with gentamicin therapeutic drug monitoring data.
  • Population PK modeling incorporating covariates: age, weight, fat-free mass, GFR, and oncology status.
  • Monte Carlo simulations to assess probability of target attainment (Cmax/MIC ≥8) and safety (trough <1 mg/L).

Main Results:

  • A one-compartment model with linear elimination described gentamicin disposition.
  • Body weight, age, and GFR significantly influenced clearance; oncology status did not.
  • Augmented renal clearance was more common in oncology patients (33.7% vs. 21.0%).
  • Doses of 6 mg/kg achieved ≥90% target attainment for MIC ≤1 mg/L, but 10 mg/kg was insufficient for MIC = 2 mg/L.

Conclusions:

  • Oncology status has minimal impact on gentamicin PK.
  • High prevalence of augmented renal clearance necessitates individualized dosing.
  • PK modeling and therapeutic drug monitoring are vital for gentamicin efficacy and safety in pediatric oncology.